We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros and Tekon Biotech Sign Distribution Agreement
News

Gyros and Tekon Biotech Sign Distribution Agreement

Gyros and Tekon Biotech Sign Distribution Agreement
News

Gyros and Tekon Biotech Sign Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros and Tekon Biotech Sign Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros AB has announced that it has appointed Tekon Biotech as exclusive distributor of its nanoliter-scale immunoassay platform Gyrolab™ xP in China, Taiwan & Hong Kong. Tekon Biotech is a leading distributor to pharmaceutical, biotechnology and academic laboratories.

Gyros’ immunoassay platform (www.gyros.com) is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.

The platform comprises Gyrolab xP workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.

“We are impressed with Tekon’s reputation for service and technical support in the region, and with a customer base including all major pharmaceutical and biotechnology companies in China, as well as the top 50 universities, Tekon is an ideal partner,” said Dan Calvo, CEO, Gyros AB. “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry, and we are delighted that Tekon will be helping to build our network of customers in China, Taiwan and Hong Kong.”

“We are excited to represent Gyros in China," said David Hadfield, CEO, Tekon Biotech in Shanghai. “With the tremendous growth in Biologics in China, plus increased demand for PK/PD and ADA testing, we see great potential for the Gyrolab platform and it’s advances in miniaturized, automated immunoassays.”

Advertisement